JJ-450

(-) -JJ-450 is a non-competitive antagonist targeting the androgen receptor (AR). (-) -JJ-450 is more potent than (+) -JJ-450 in inhibiting androgen-induced AR activity, and the mechanism of AR inhibition by (+) -JJ-450 is different from that of Enzalutamide (MDV3100) (HY-70003), which may target the ligand binding domain (LBD) of AR. (-) -JJ-450 inhibits the transcriptional activity of wild-type AR and mutant ARF876L by inhibiting AR nuclear translocation and promoting nuclear degradation of unbound AR. (-) -JJ-450 can be used in the study of castration-resistant prostate cancer (CRPC) resistant to Enzalutamide[1].

1998094-23-7

12352005

Androgen Receptor

Vitamin D Related/Nuclear Receptor

Cancer-programmed cell death

Cancer

O=C([C@H]1C[C@H]1C2=CC=C(C=C2)F)N3CCN(CC3)C4=CC(Cl)=CC=C4C

C21H22ClFN2O

372.86

[1]Cole RN, et al. (+) -JJ-74-138 is a Novel Noncompetitive Androgen Receptor Antagonist. Mol Cancer Ther. 2022 Apr 1;21 (4) :483-492.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-403733A/

Reference compound1

No Development Reported